BeiGene (NASDAQ:BGNE) Stock Price Down 2.4%

BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) fell 2.4% on Friday . The stock traded as low as $126.97 and last traded at $128.77. 17,319 shares traded hands during trading, a decline of 93% from the average session volume of 256,444 shares. The stock had previously closed at $131.96.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BGNE. Sanford C. Bernstein dropped their price objective on shares of BeiGene from $196.00 to $161.00 and set a "market perform" rating on the stock in a report on Wednesday, March 27th. JPMorgan Chase & Co. upped their target price on shares of BeiGene from $184.00 to $186.00 and gave the stock an "overweight" rating in a report on Tuesday, March 19th. Guggenheim lowered their target price on shares of BeiGene from $350.00 to $345.00 and set a "buy" rating on the stock in a report on Tuesday, February 27th. Finally, Bank of America lowered their target price on shares of BeiGene from $179.30 to $164.30 and set a "neutral" rating on the stock in a report on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $251.70.

BeiGene Stock Down 1.8 %

The company has a current ratio of 2.32, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. The stock's 50-day simple moving average is $155.43 and its 200-day simple moving average is $168.61. The firm has a market capitalization of $12.39 billion, a P/E ratio of -15.24 and a beta of 0.61.

BeiGene (NASDAQ:BGNE - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The business had revenue of $634.40 million during the quarter, compared to the consensus estimate of $632.52 million. During the same period in the prior year, the firm posted ($4.29) EPS. The firm's quarterly revenue was up 66.9% compared to the same quarter last year. As a group, research analysts predict that BeiGene, Ltd. will post -8.87 earnings per share for the current fiscal year.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 37,668 shares of the firm's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the completion of the sale, the chief executive officer now owns 12,332 shares in the company, valued at approximately $2,022,694.64. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO John Oyler sold 37,668 shares of BeiGene stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total value of $6,178,305.36. Following the completion of the transaction, the chief executive officer now directly owns 12,332 shares in the company, valued at approximately $2,022,694.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The disclosure for this sale can be found here. Insiders sold a total of 64,781 shares of company stock worth $10,222,381 in the last quarter. Insiders own 7.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BGNE. PNC Financial Services Group Inc. boosted its holdings in BeiGene by 26.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 244 shares of the company's stock valued at $54,000 after purchasing an additional 51 shares during the period. Toronto Dominion Bank boosted its holdings in BeiGene by 166.4% in the 3rd quarter. Toronto Dominion Bank now owns 333 shares of the company's stock valued at $60,000 after purchasing an additional 208 shares during the period. Knights of Columbus Asset Advisors LLC boosted its holdings in BeiGene by 20.5% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company's stock valued at $80,000 after purchasing an additional 76 shares during the period. Benjamin F. Edwards & Company Inc. bought a new stake in shares of BeiGene during the 4th quarter worth $98,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of BeiGene by 73.5% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 694 shares of the company's stock worth $125,000 after acquiring an additional 294 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.